ArticleMicrobial cell factories2025
Characterization and bioactivities of glutaminase-free L-asparaginase from Salinicola acorporae S4-41.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe medical community has long searched for a safer and more effective cancer treatment method. Clinically, L-asparaginase derived from bacteria has shown promising results. However, it carries the risk of immunological and hypersensitive reactions due to its interaction with glutaminase. Therefore, finding a new source of glutaminase-free L-asparaginase (ASNase) is important.
resultsIn this study, 35 bacterial isolates from 12 saline environmental samples were tested for ASNase, and the most promising bacterium was identified as Salinicola acroporae S4-41. This bacterium produces intracellular ASNase, which could treat cancer with fewer side effects. Agitation enhanced production by nearly five-fold compared to static conditions. The enzyme activity peaked at 40 °C and pH 8 after 96 h in a medium containing 100 g L-1 of NaCl, 2 g L-1 of glucose, and 15 g L-1 of L-asparagine. The purified enzyme was 65 kDa in size, with optimal activity in 1 M NaCl, 0.05 M L-asparagine, 0.1% DMSO, urea, and Tween 80 at pH 8 and 40 °C. The enzyme’s kinetics showed a Km of 0.007271 mM and a Vmax of 84.31 U mL⁻¹ min⁻¹. Pure ASNase significantly inhibited the growth of cancer cell lines NB4, MCF-7, and HepG-2. S. acroporae produces fewer harmful ASNase enzymes, which could improve cancer treatment. This is the first report of ASNase production from S. acroporae S4-41.
conclusionSalinicola acroporae S4-41 (GenBank accession number SUB12091824; OP521775), a halotolerant bacterium isolated from the rhizosphere soil of cogon grass (Imperata cylindrica), was found to produce glutaminase-free L-asparaginase, a significant benefit for lowering treatment-related side effects, making it a promising candidate for safer therapeutic applications. Quantitative analysis revealed an activity of 10.72 U/mL, which increased significantly under optimized physicochemical conditions. Its maximal output (58.76 U/mL) attained at 40 °C and 1.5% L-asparagine, and it also showed notable pH stability at pH 8. The isolate showed improved enzyme output under shaking conditions and adaptability over a wide salinity range (0–25% NaCl). Although activity decreased with ethanol and inhibitors such SDS and EDTA, the isolated enzyme maintained significant stability in the face of heat, pH, and nonionic surfactants (Tween 80, DMSO). These findings demonstrate the enzyme’s surfactant-stable, halotolerant, and thermotolerant characteristics could serve as a safer alternative to currently used bacterial asparaginases by reducing adverse immunological reactions, highlighting its potential for use in pharmaceutical and biotechnological applications. To confirm its medicinal potential and increase its industrial utility, more research is necessary, especially in vivo assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.